Drug Information Association

From Wikipedia, the free encyclopedia
Jump to: navigation, search

The Drug Information Association (DIA) is a 501(c)(3) non-profit association registered in Pennsylvania[1] and headquartered in Washington DC, USA.

The DIA was founded in 1964 in Maryland, United States, by a group of thirty pharmaceutical professionals, medical writers, industry professionals and academicians. The goal of DIA was to facilitate communications and foster cooperative efforts among professionals working in health care industries primarily engaged in drug development, medical communications and health information.[2] The founding of DIA was closely tied to the passing of the Kefauver Harris Amendment after the devastation of thalidomide, a sedative used to treat morning sickness in pregnant women that was causing birth defects. Thomas W. Teal, a pharmaceutical executive and DIA’s founder, strongly supported a method of providing accurate up-to -date pharmaceutical information, thus the founding of DIA.[2]

DIA is a neutral platform and is independent of stakeholders such as industry, patient organisations, payers, academia and government agencies. This ensures an unbiased environment for the Associations’ activities and goals. DIA provides educational and professional development opportunities for individuals working in the pharmaceutical and medical product development-related fields.

DIA provides regular publications to its members including: The Global Forum, a news and information resource that keeps members advised of current trends in the health care arena; Therapeutic Innovation & Regulatory Science, DIA’s official peer-reviewed journal (SAGE Publishers); and the CSO Directory, an annual, international digital reference guide compiling information from drug development and clinical trial companies.[2]

For 2011, DIA reported operating losses for the two years prior, indicated in 990 filings with the IRS.[3] During 2011, the salaries of top executives totaled $2.7 million on an operating loss of $1.5 million.


  • Professional development through conferences and meetings.
  • Industry "Thought leadership" in "regulatory science" and regulatory affairs
  • Training courses including in-house training, certificate programs and online training.
  • Continuing education for healthcare professionals.
  • Publications including the peer reviewed journal "Therapeutic Innovation and Regulatory Science".
  • Career guidance and job opportunities.
  • Creation of reference models including that for Trial master files


  1. ^ "Drug Information Association Inc GuideStar Summary". GuideStar. Retrieved 7 January 2015. 
  2. ^ a b c "About DIA". diahome.org. Retrieved 12 Jun 2014. 
  3. ^ Drug Information Association Form 990 filing, (2011)

External links[edit]